Quince Therapeutics
As of the edition of 20 October 2026, Quince Therapeutics runs 4 drugs.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Cortexyme Inc.: renamed in 2022
- OrphAI Therapeutics: acquired in 2026; successor Cortexyme Inc.
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 1 |
| Status not established | 3 |
| Total | 4 |
Where its trials are
- Nervous system: 3 trials led
- Mental health: 2 trials led
- Nutrition and metabolism: 2 trials led